Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.56 USD
Change Today -0.02 / -0.78%
Volume 5.6K
TRGT On Other Exchanges
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

targacept inc (TRGT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $3.23
52 Week Low
05/14/15 - $2.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TARGACEPT INC (TRGT)

Related News

No related news articles were found.

targacept inc (TRGT) Related Businessweek News

No Related Businessweek News Found

targacept inc (TRGT) Details

Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates include TC-6499 for the treatment of diabetic gastroparesis; and TC-5619 and TC-6987, which are novel small molecules that are selective for the a7 NNR. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

19 Employees
Last Reported Date: 07/23/15
Founded in 1997

targacept inc (TRGT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $644.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $294.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $385.7K
Compensation as of Fiscal Year 2014.

targacept inc (TRGT) Key Developments

Targacept, Inc. Announces Resignation of Scott N. Cullison as Vice President, Business Development, Effective May 31, 2015

Targacept, Inc. and Catalyst Biosciences, Inc. entered into an agreement and plan of merger on March 5, 2015, as amended on May 6, 2015. The company terminated the employment of Scott N. Cullison, Vice President, Business Development of the company, effective May 31, 2015. Under the company’s previously disclosed employment agreement with Mr. Cullison dated October 8, 2014, Mr. Cullison will receive severance benefits consistent with a termination other than for just cause in connection with but prior to an anticipated change in control of the company, within the meaning of the employment agreement. Mr. Cullison’s termination was not due to any disagreement relating to the company’s operations, policies or practices.

Targacept Announces Negative Top-Line Results from Exploratory Study of Tc-6499 in Diabetic Gastroparesis

Targacept, Inc. announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. In the trial, TC-6499 did not meet the primary endpoint of the study, change in gastric emptying half-time (BT_t1/2), as measured by a carbon (13C) labeled gastric emptying breath test, relative to placebo.

Targacept, Inc. Terminates Employment of Steven M. Toler, Vice President, Clinical Pharmaceutical Sciences, Effective March 31, 2015

On March 11, 2015, Targacept, Inc. terminated the employment of Steven M. Toler, PharmD., Ph.D., Vice President, Clinical Pharmaceutical Sciences of the Company, effective March 31, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRGT:US $2.56 USD -0.02

TRGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $85.09 USD -0.59
Novartis AG SFr.100.30 CHF +0.10
Pfizer Inc $35.76 USD +0.41
ProMIS Neurosciences Inc C$0.06 CAD +0.005
View Industry Companies

Industry Analysis


Industry Average

Valuation TRGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 351.6x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARGACEPT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at